Last reviewed · How we verify
NCT05623943
Comparison of Cerebral Artery Pressure Gradient and Cerebral Blood Flow Measured by Arterial Spin Labeling
trial testing Endovascular treatment in Stroke, Ischemic in 25 participants. Completed in 1 February 2023.
1 January 2023
Quick facts
| Lead sponsor | Xuanwu Hospital, Beijing |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 25 |
| Start date | 1 June 2019 |
| Primary completion | 1 January 2023 |
| Estimated completion | 1 February 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- Endovascular treatment
Conditions studied
- Stroke, Ischemic — all drugs for Stroke, Ischemic →
- Intracranial Atherosclerosis — all drugs for Intracranial Atherosclerosis →
Sponsor
Xuanwu Hospital, Beijing
Who can join
40 and older, any sex, with Stroke, Ischemic or Intracranial Atherosclerosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to explore the ability of intravascular pressure gradients to identify hemodynamic disturbance in patients with intracranial atherosclerotic diseases (ICAS). The main questions that aim to answer are: * The correlation between intravascular pressure gradient and cerebral blood flow (CBF) * The threshold for intravascular pressure gradients to predict hemodynamic disturbance in ICAS Patients will undergo intravascular pressure measurement and arterial spin labeling (ASL) for CBF during pre- and post-operation respectively.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05623943
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Endovascular treatment
Trials testing the same drug.
- NCT07323368 — Advancing Reperfusion Therapy for Ischemic Stroke: Perfusion-guided Endovascular Intervention for Medium Vessel Occlusio · NA · recruiting
- NCT07263308 — Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Therapy -2 · Phase 3 · recruiting
- NCT07315633 — An Innovative CFD-based Dosimetry and Pre-treatment Planning Platform to Support Personalized Transarterial Therapies fo · recruiting
- NCT06580730 — Endovascular Treatment for Stroke Post 1 Day （24 Hours） · NA · not yet recruiting
- NCT06588543 — Patient-specific Planning of Minimally Invasive Brain Interventions Based on Vascular-hemodynamic Mapping · recruiting
Other recruiting trials for Stroke, Ischemic
Currently open trials in the same condition.
- NCT07456956 — HIIT vs MCIT for Stroke-Related Sarcopenia in Ischemic Stroke · NA · recruiting
- NCT06658197 — Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke · Phase 3 · recruiting
- NCT07282041 — Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis · Phase 2, PHASE3 · recruiting
- NCT07135089 — Improving Neuroprotective Strategy for Ischemic Stroke Before Endovascular Thrombectomy by Intravenous Tirofiban · Phase 3 · recruiting
- NCT07047014 — Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Tenecteplase in Medium Vessel Occlusion (MeVO) for Acute Ische · Phase 3 · recruiting
Other Xuanwu Hospital, Beijing trials
Trials by the same sponsor.
- NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
- NCT07519044 — Safety and Efficacy of Adjunctive GM1 to Mechanical Thrombectomy for Acute Anterior Circulation Large Vessel Occlusion · Phase 4 · not yet recruiting
- NCT07396077 — Pre-operative Risk Assessment Combined With Targeted Intervention in the Chinese Elderly With Spine Surgery II · NA · not yet recruiting
- NCT07457125 — The Effect of CB-Exo-A600 in Mild to Moderate Alzheimer's Disease · Phase 1, PHASE2 · not yet recruiting
- NCT07479446 — Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle Surgery · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05623943 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xuanwu Hospital, Beijing
- Last refreshed: 27 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05623943.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing